Marcain Polyamp Steripack (Bupivacaine Hydrochloride, Anhydrous)

Bupivacaine hydrochloride is a long‑acting amide local anesthetic used to block nerve conduction in regional anesthesia.

• Epidural anesthesia: Provides prolonged sensory block for labor, delivery, or postoperative pain control.
• Infiltration anesthesia: Produces localized numbness for minor surgical or dental procedures.
• Peripheral nerve block: Offers targeted anesthesia for limb surgeries.

• Bupivacaine hydrochloride reversibly inhibits voltage‑gated sodium channels on neuronal membranes, preventing the initiation and propagation of action potentials. This blockade halts nerve impulse transmission, resulting in loss of sensation and pain in the area where the drug is administered.

Adverse reactions may occur following administration of bupivacaine hydrochloride.

Common Side Effects

• Injection site pain or irritation
• Transient hypotension
• Bradycardia
• Nausea or vomiting
• Dizziness or light‑headedness
• Metallic taste in the mouth

Serious or Rare Side Effects

• Cardiac arrhythmias or cardiac arrest
• Seizures
• Respiratory depression or apnea
• Severe allergic reaction (anaphylaxis)
• Prolonged motor block
• Methemoglobinemia (rare)

When using Marcain Polyamp Steripack, clinicians should observe the following precautions.

• Allergy assessment: Verify no known hypersensitivity to amide‑type local anesthetics.
• Dose minimisation: Use the lowest effective dose to achieve the desired block.
• Cardiovascular monitoring: Observe heart rate and blood pressure during and after injection.
• Avoid intravascular injection: Aspirate before administration to prevent systemic toxicity.
• Hepatic impairment: Adjust dosing in patients with significant liver disease.
• Pregnancy considerations: Use only if the anticipated benefit outweighs potential risk to the fetus.
• Store at room temperature: Keep in the original packaging, protect from light and moisture.

Bupivacaine hydrochloride may interact with other medicines, requiring attention to potential additive effects.

Major Interactions (Avoid)

• Concurrent use of other local anesthetics: Increases risk of cumulative systemic toxicity.
• Class I antiarrhythmic agents (e.g., quinidine, procainamide): Heighten cardiotoxic potential.
• Beta‑blockers: May exacerbate bradycardia and hypotension.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): May raise plasma concentrations of bupivacaine.
• Diuretics: Can alter plasma protein binding, affecting free drug levels.
• General anesthetics (e.g., propofol, volatile agents): May potentiate central nervous system depression.